MedPath

acetylcysteine as a Preventive Measure for Contrast Induced Nephropathy in Intensive Care Patients with Renal Insufficiency.

Conditions
Renal insufficiency (not yet requiring renal replacement therapy)
Registration Number
NL-OMON20378
Lead Sponsor
one
Brief Summary

Will be written after completion of study and anlysis of results

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Not specified
Target Recruitment
246
Inclusion Criteria

1. (Chronic or acute) renal insufficiency (not presently on renal replacement therapy) defined as a plasma creatinine > 180 ìmol/L;

2. Planned diagnostic imaging procedure requiring the use of intravenous radiographic contrast agents;

Exclusion Criteria

1. Pregnancy;

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1. Rise in plasma creatinine > 25% within 48 hours after contrast administration.<br /><br>Need for CVVH therapy at any moment during stay in ICU;<br /><br>2. Duration of CVVH therapy, if initiated;<br><br />3. Renal insufficiency (for which ongoing renal replacement therapy) at ICU-discharge .
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath